Business
Nuvec resource changes
Nuvec resource changes.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 6494H N4 Pharma PLC 16 November 2018 \n\n16 November 2018\nN4 Pharma Plc\n(\"N4 Pharma\" or the \"Company\")\n \nNuvec® resource changes\n \nN4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments, is pleased to announce that it has engaged Melody Janssen PhD under a consultancy contract to lead its internal and external research program for its novel delivery system, Nuvec®.\n \nMelody is an Internationally acknowledged expert in virology and immunology and brings a wealth of experience to the Company's research program. Melody has extensive experience of different delivery systems and was formerly Head of R&D and pre-clinical development for Mymetics, a leading biotech company in vaccine development based on a proprietary virosome technology.\n \nIn conjunction with Melody's appointment, Andrew Leishman will step down as Head of the Nuvec® division with effect from 10 January 2019, to enable him to take up other consultancy positions. Thereafter, he will continue to work with and advise the Company as a consultant.\n \n \nNigel Theobald, CEO of N4 Pharma commented:\n \n\"We are delighted to welcome Melody to the N4 team and her wealth of experience will be invaluable to help ensure our Nuvec® pharmacology program continues to provide relevant results for potential collaborators.\" \n \n \nEnquiries:\n \n\n\n\nN4 Pharma Plc\nNigel Theobald, CEO\n\n\n \nVia Alma PR\n \n\n\n\n\nAllenby Capital Limited\nJames Reeve/Virginia Bull/Asha Chotai\n \n\n\nTel: +44(0)203 328 5656\n\n\n\n\nAlma PR\nJosh Royston\nRobyn Fisher\n\n\n \nTel: +44(0)778 090 1979\nTel: +44(0)754 070 6191\n\n\n\n \nAbout N4 Pharma\nN4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®\nNuvec® has shown to be capable of loading and delivering mRNA and pDNA into cells to the required level needed to generate an immune response. Further work will be undertaken for the direct loading and delivery of peptides and proteins using Nuvec®.\n \nN4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatme...